Document Detail


Topical buparvaquone formulations for the treatment of cutaneous leishmaniasis.
MedLine Citation:
PMID:  17227619     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
As the part of a study to develop buparvaquone (BPQ) formulations for the treatment of cutaneous leishmaniasis, the topical delivery of BPQ and one of its prodrugs from a range of formulations was evaluated. In previous studies, BPQ and its prodrugs were shown to be potent antileishmanials in-vitro, with ED50 values in the nanomolar range. 3-Phosphono-oxymethyl-buparvaquone (3-POM-BPQ) was the most potent antileishmanial and was chosen, together with the parent drug, for further investigation. The ability of the parent and prodrug formulations to cross human and murine skin was tested in-vitro using the Franz diffusion cells. Formulations intended for topical application containing either BPQ or 3-POM-BPQ were developed using excipients that were either acceptable for topical use (GRAS or FDA inactive ingredients) or currently going through the regulatory process. BPQ was shown to penetrate both human epidermal membranes and full thickness BALB/c skin from a range of formulations (gels, emulsions). Similarly, 3-POM-BPQ penetrated full-thickness BALB/c skin from several gel formulations. In-vitro binding studies showed that BPQ bound melanin in a dose-dependent manner and preferably bound to delipidized skin over untreated BALB/c skin (on a weight to weight basis). The results confirm that BPQ and its prodrug 3-POM-BPQ can penetrate the skin from several formulations, making them potentially interesting candidates for further investigation of topical formulations using in-vivo models of cutaneous leishmaniasis.
Authors:
Tracy Garnier; Antti Mäntylä; Tomi Järvinen; M Jayne Lawrence; Marc B Brown; Simon L Croft
Related Documents :
1735499 - Establishing a program of oocyte donation in brazil.
11529359 - Correlation between human follicular diameter and oocyte recovery, metaphase ii oocytes...
12387339 - Vitrification of yunnan yellow cattle oocytes: work in progress.
14531649 - Intracytoplasmic sperm injection and conventional in vitro fertilization are complement...
7736649 - Pure fsh (metrodin) for ovarian stimulation in the ivf-et programme.
20031019 - Pronuclear zygote score following intracytoplasmic injection of hyaluronan-bound sperma...
17765669 - Prediction and perinatal outcomes of fetal growth restriction.
25062519 - Buprenorphine for the treatment of opioid dependence in pregnancy.
10802839 - Neonatal outcome when delivery follows a borderline immature lecithin to sphingomyelin ...
Publication Detail:
Type:  In Vitro; Journal Article    
Journal Detail:
Title:  The Journal of pharmacy and pharmacology     Volume:  59     ISSN:  0022-3573     ISO Abbreviation:  J. Pharm. Pharmacol.     Publication Date:  2007 Jan 
Date Detail:
Created Date:  2007-01-17     Completed Date:  2007-04-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0376363     Medline TA:  J Pharm Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  41-9     Citation Subset:  IM    
Affiliation:
School of Pharmacy, University of Hertfordshire, College Lane, Hatfield AL10 9AB, UK. t.garnier@herts.ac.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Cutaneous
Animals
Antiprotozoal Agents / chemistry,  metabolism*
Chemistry, Pharmaceutical
Ethanol / chemistry
Female
Humans
Leishmaniasis, Cutaneous
Melanins / metabolism
Mice
Mice, Inbred BALB C
Myristates / chemistry
Naphthoquinones / chemistry,  metabolism*
Phosphoric Acid Esters / chemistry,  metabolism*
Polyethylene Glycols / chemistry
Prodrugs / chemistry,  metabolism*
Propylene Glycol / chemistry
Skin / metabolism
Skin Absorption*
Chemical
Reg. No./Substance:
0/3-phosphonooxymethylbuparvaquone; 0/Antiprotozoal Agents; 0/Melanins; 0/Myristates; 0/Naphthoquinones; 0/Phosphoric Acid Esters; 0/Polyethylene Glycols; 0/Prodrugs; 110-27-0/isopropyl myristate; 57-55-6/Propylene Glycol; 64-17-5/Ethanol; 88426-33-9/buparvaquone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Modification of the crystal habit of celecoxib for improved processability.
Next Document:  Image analysis by pulse coupled neural networks (PCNN)--a novel approach in granule size characteriz...